Boehringer Ingelheim Commits $5 Million Over Three Years to a WHO Foundation Obesity and Metabolic Health Program
Boehringer Ingelheim and the WHO Foundation announced on Thursday, September 24, 2026 a three-year collaboration, funded by a $5 million contribution from Boehringer, to help health systems in resource-limited settings monitor and care for obesity and related metabolic conditions. The program is meant to support the WHO Acceleration Plan to Stop Obesity (2022-2030) and to bring health and non-health sectors, along with people living with noncommunicable diseases, into policy discussions. The announcement did not name countries or include access to any specific medicine; Boehringer's obesity pipeline includes survodutide, a GLP-1/glucagon receptor agonist licensed from Zealand Pharma.